Cargando…
Statin use and all-cause and cancer mortality: BioBank Japan cohort
BACKGROUND: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350595/ https://www.ncbi.nlm.nih.gov/pubmed/28196737 http://dx.doi.org/10.1016/j.je.2016.12.011 |
_version_ | 1782514693508694016 |
---|---|
author | Yokomichi, Hiroshi Nagai, Akiko Hirata, Makoto Tamakoshi, Akiko Kiyohara, Yutaka Kamatani, Yoichiro Muto, Kaori Ninomiya, Toshiharu Matsuda, Koichi Kubo, Michiaki Nakamura, Yusuke Yamagata, Zentaro |
author_facet | Yokomichi, Hiroshi Nagai, Akiko Hirata, Makoto Tamakoshi, Akiko Kiyohara, Yutaka Kamatani, Yoichiro Muto, Kaori Ninomiya, Toshiharu Matsuda, Koichi Kubo, Michiaki Nakamura, Yusuke Yamagata, Zentaro |
author_sort | Yokomichi, Hiroshi |
collection | PubMed |
description | BACKGROUND: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. METHODS: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. Kaplan–Meier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. RESULTS: Our cohort included 41,930 patients with mean ages of 64–66 years and mean body mass indices of 24–25 kg/m(2). Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. CONCLUSIONS: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statin monotherapy could potentially reduce any-organ- and colorectal cancer-related mortality. |
format | Online Article Text |
id | pubmed-5350595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-53505952017-03-21 Statin use and all-cause and cancer mortality: BioBank Japan cohort Yokomichi, Hiroshi Nagai, Akiko Hirata, Makoto Tamakoshi, Akiko Kiyohara, Yutaka Kamatani, Yoichiro Muto, Kaori Ninomiya, Toshiharu Matsuda, Koichi Kubo, Michiaki Nakamura, Yusuke Yamagata, Zentaro J Epidemiol Original Article BACKGROUND: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. METHODS: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. Kaplan–Meier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. RESULTS: Our cohort included 41,930 patients with mean ages of 64–66 years and mean body mass indices of 24–25 kg/m(2). Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. CONCLUSIONS: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statin monotherapy could potentially reduce any-organ- and colorectal cancer-related mortality. Elsevier 2017-02-11 /pmc/articles/PMC5350595/ /pubmed/28196737 http://dx.doi.org/10.1016/j.je.2016.12.011 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Yokomichi, Hiroshi Nagai, Akiko Hirata, Makoto Tamakoshi, Akiko Kiyohara, Yutaka Kamatani, Yoichiro Muto, Kaori Ninomiya, Toshiharu Matsuda, Koichi Kubo, Michiaki Nakamura, Yusuke Yamagata, Zentaro Statin use and all-cause and cancer mortality: BioBank Japan cohort |
title | Statin use and all-cause and cancer mortality: BioBank Japan cohort |
title_full | Statin use and all-cause and cancer mortality: BioBank Japan cohort |
title_fullStr | Statin use and all-cause and cancer mortality: BioBank Japan cohort |
title_full_unstemmed | Statin use and all-cause and cancer mortality: BioBank Japan cohort |
title_short | Statin use and all-cause and cancer mortality: BioBank Japan cohort |
title_sort | statin use and all-cause and cancer mortality: biobank japan cohort |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350595/ https://www.ncbi.nlm.nih.gov/pubmed/28196737 http://dx.doi.org/10.1016/j.je.2016.12.011 |
work_keys_str_mv | AT yokomichihiroshi statinuseandallcauseandcancermortalitybiobankjapancohort AT nagaiakiko statinuseandallcauseandcancermortalitybiobankjapancohort AT hiratamakoto statinuseandallcauseandcancermortalitybiobankjapancohort AT tamakoshiakiko statinuseandallcauseandcancermortalitybiobankjapancohort AT kiyoharayutaka statinuseandallcauseandcancermortalitybiobankjapancohort AT kamataniyoichiro statinuseandallcauseandcancermortalitybiobankjapancohort AT mutokaori statinuseandallcauseandcancermortalitybiobankjapancohort AT ninomiyatoshiharu statinuseandallcauseandcancermortalitybiobankjapancohort AT matsudakoichi statinuseandallcauseandcancermortalitybiobankjapancohort AT kubomichiaki statinuseandallcauseandcancermortalitybiobankjapancohort AT nakamurayusuke statinuseandallcauseandcancermortalitybiobankjapancohort AT statinuseandallcauseandcancermortalitybiobankjapancohort AT yamagatazentaro statinuseandallcauseandcancermortalitybiobankjapancohort |